We found for
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?

The Lower Drug Costs Now Act and Pharmaceutical Innovation
